Β-マンノシダーゼ

β-マンノシダーゼ
識別子
EC番号 3.2.1.25
CAS登録番号 9025-43-8
データベース
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB構造 RCSB PDB PDBj PDBe PDBsum
遺伝子オントロジー AmiGO / QuickGO
検索
PMC articles
PubMed articles
NCBI proteins
テンプレートを表示

β-マンノシダーゼ(Beta-Mannosidase、EC 3.2.1.25)は、β-D-マンノシドの非還元末端からβ-D-マンノースを切り出す酵素である。系統名は、β-D-マンノシド マンノヒドロラーゼ(beta-D-mannoside mannohydrolase)。である。マンナナーゼ(mannanase)、マンナーゼ(mannase)等とも言う。ヒトでは、MANBA遺伝子がコードする[1][2][3][4][5][6]。

この遺伝子は、GHファミリー2の酵素をコードする。コードされた蛋白質はリソソームに局在し、ここで、N-結合オリゴ糖の異化経路の最後のエキソグリコシダーゼとして働く。この遺伝子の変異は、幅広い神経障害を引き起こすリソソーム蓄積症であるβ-マンノシドーソスを引き起こす[1]。

出典

  1. ^ a b “Entrez Gene: mannosidase”. 2013年8月17日閲覧。
  2. ^ Chen H, Leipprandt JR, Traviss CE, Sopher BL, Jones MZ, Cavanagh KT, Friderici KH (February 1995). “Molecular cloning and characterization of bovine beta-mannosidase”. J. Biol. Chem. 270 (8): 3841–8. doi:10.1074/jbc.270.8.3841. PMID 7876128. 
  3. ^ Adams, M., Richtmyer, N.K. and Hudson, C.S. (1943). “Some enzymes present in highly purified invertase preparations; a contribution to the study of fructofuranosidases, galactosidases, glucosidases and mannosidases”. J. Am. Chem. Soc. 65 (7): 1369–1380. doi:10.1021/ja01247a029. 
  4. ^ Bartholomew, B.A. and Perry, A.L. (1973). “The properties of synovial fluid β-mannosidase activity”. Biochim. Biophys. Acta 315 (1): 123–127. doi:10.1016/0005-2744(73)90136-8. PMID 4743897. 
  5. ^ Deuel, H., Lewuenberger, R. and Huber, G. (1950). “Über den enzymatischen Abbau von Carubin, dem Galaktomannan aus Ceratonia siliqua L”. Helv. Chim. Acta 33 (4): 942–946. doi:10.1002/hlca.19500330424. 
  6. ^ Hylin, J.W. and Sawai, K. (1964). “The enzymatic hydrolysis of Leucaena glauca galactomannan. Isolation of crystalline galactomannan depolymerase”. J. Biol. Chem. 239: 990–992. PMID 14165949. 

関連文献

  • Bolmstedt A, Sjölander S, Hansen JE, et al. (1996). “Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response”. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12 (3): 213–20. doi:10.1097/00042560-199607000-00001. PMID 8673525. 
  • Kalsi G, Kuo PH, Aliev F, et al. (2010). “A systematic gene-based screen of chr4q22-q32 identifies association of a novel susceptibility gene, DKK2, with the quantitative trait of alcohol dependence symptom counts”. Hum. Mol. Genet. 19 (12): 2497–506. doi:10.1093/hmg/ddq112. PMC 2876884. PMID 20332099. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876884/. 
  • Levade T, Graber D, Flurin V, et al. (1994). “Human beta-mannosidase deficiency associated with peripheral neuropathy”. Ann. Neurol. 35 (1): 116–9. doi:10.1002/ana.410350119. PMID 8285582. 
  • Hu H, Shioda T, Moriya C, et al. (1996). “Infectivities of human and other primate lentiviruses are activated by desialylation of the virion surface”. J. Virol. 70 (11): 7462–70. PMC 190813. PMID 8892864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC190813/. 
  • Yeh JC, Seals JR, Murphy CI, et al. (1993). “Site-specific N-glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus expression system”. Biochemistry 32 (41): 11087–99. doi:10.1021/bi00092a019. PMID 8218172. 
  • Sabourdy F, Labauge P, Stensland HM, et al. (2009). “A MANBA mutation resulting in residual beta-mannosidase activity associated with severe leukoencephalopathy: a possible pseudodeficiency variant”. BMC Med. Genet. 10: 84. doi:10.1186/1471-2350-10-84. PMC 2745377. PMID 19728872. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745377/. 
  • Hosgood HD, Zhang L, Shen M, et al. (2009). “Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity”. Occup Environ Med 66 (12): 848–53. doi:10.1136/oem.2008.044024. PMC 2928224. PMID 19773279. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928224/. 
  • Alkhayat AH, Kraemer SA, Leipprandt JR, et al. (1998). “Human beta-mannosidase cDNA characterization and first identification of a mutation associated with human beta-mannosidosis”. Hum. Mol. Genet. 7 (1): 75–83. doi:10.1093/hmg/7.1.75. PMID 9384606. 
  • Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). “Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes”. Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356129/. 
  • Papandreou MJ, Fenouillet E (1997). “Effect of various glycosidase treatments on the resistance of the HIV-1 envelope to degradation”. FEBS Lett. 406 (1–2): 191–5. doi:10.1016/S0014-5793(97)00273-1. PMID 9109416. 
  • Gao J, Arbman G, He L, et al. (2008). “MANBA polymorphism was related to increased risk of colorectal cancer in Swedish but not in Chinese populations”. Acta Oncol 47 (3): 372–8. doi:10.1080/02841860701644052. PMID 17899454. 
  • Robinson WE, Montefiori DC, Mitchell WM (1987). “Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1) pathogenesis”. AIDS Res. Hum. Retroviruses 3 (3): 265–82. doi:10.1089/aid.1987.3.265. PMID 2829950. 
  • Montefiori DC, Robinson WE, Mitchell WM (1988). “Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1”. Proc. Natl. Acad. Sci. U.S.A. 85 (23): 9248–52. doi:10.1073/pnas.85.23.9248. PMC 282716. PMID 3264072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC282716/. 
  • Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC528928/. 
  • Fenouillet E, Jones I, Powell B, et al. (1993). “Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain”. J. Virol. 67 (1): 150–60. PMC 237347. PMID 8093218. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237347/. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2002). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC139241/. 
  • Land A, Braakman I (2001). “Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum”. Biochimie 83 (8): 783–90. doi:10.1016/S0300-9084(01)01314-1. PMID 11530211. 
  • Blough HA, Pauwels R, De Clercq E, et al. (1986). “Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins”. Biochem. Biophys. Res. Commun. 141 (1): 33–8. doi:10.1016/S0006-291X(86)80330-8. PMID 3099781. 
  • Hart ML, Saifuddin M, Spear GT (2003). “Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin”. J. Gen. Virol. 84 (Pt 2): 353–60. doi:10.1099/vir.0.18734-0. PMID 12560567.